MIRA Pharmaceuticals is a clinical-stage pharmaceutical development company focused on neurologic, neuropsychiatric, metabolic, and addiction-related disorders. The company completed a Phase 1 clinical trial for Ketamir-2 (oral NMDA receptor modulator) in healthy volunteers, reporting no serious adverse events or dose-limiting toxicities, with final analyses ongoing. A Phase 2a clinical trial for Ketamir-2 in chemotherapy-induced peripheral neuropathy (CIPN) is planned for the first half of 2026, subject to regulatory feedback and site readiness. MIRA-55, a novel oral, non-psychoactive cannabinoid analog, is in preclinical development for inflammatory pain and central nervous system conditions, showing analgesic and anti-inflammatory activity without typical cannabinoid CNS adverse effects. The company acquired SKNY Pharmaceuticals, Inc. on September 29, 2025, adding SKNY-1, a preclinical-stage oral therapeutic, to its pipeline. SKNY-1, designed to modulate CB1, CB2, and MAO-B pathways, demonstrated reductions in body weight, food consumption, and nicotine-seeking behavior in preclinical models without muscle loss or adverse CNS effects. The U.S. Drug Enforcement Administration (DEA) concluded that Ketamir-2, MIRA-55, and SKNY-1 are not currently considered controlled substances, which may facilitate their clinical development and commercialization. MIRA Pharmaceuticals reported a net loss of $10.4 million for the year ended December 31, 2025, an increase from $7.9 million in 2024. The company's accumulated deficit reached $39.6 million as of December 31, 2025. Cash and cash equivalents stood at $6.3 million as of December 31, 2025. The independent auditor's report includes an explanatory paragraph raising substantial doubt about the company's ability to continue as a going concern. Management expects current cash to fund operations into at least the first quarter of 2027 but acknowledges the need for additional capital. The company raised $6.7 million from At The Market (ATM) financings in 2025 and $3.6 million in 2024. CEO Erez Aminov received performance-based compensation totaling $5,304,174 in 2025, including a $80,753 cash bonus and 83,500 vested restricted stock units (valued at approximately $86,000) for achieving a Phase 1 clinical milestone. Kelly Stackpole informed the company on March 30, 2026, that he would not be joining the Board as a director candidate.